MTOR and neoplasm: Martinelli et al. revealed that the selective MEK1/2 inhibitor pimasertib combined with the dual PI3K/mTOR inhibitor BEZ235 or with sorafenib caused significant tumor growth delays and increased survival in mice as compared to single agent treatment thereby suggesting that dual blockade of MAPK and PI3K pathways could overcome intrinsic resistance to MEK inhibition [43].